RSCM
CORT icon

Rock Springs Capital Management’s Corcept Therapeutics CORT Stock Holding History

Rock Springs Capital Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.26M Buy
72,000
+21,750
+43% +$1.31M 0.31% 68
2026
Q1 		$2.03M Hold
50,250
– – 0.12% 90
2025
Q4 		$1.75M Buy
+50,250
New +$3.95M 0.09% 92

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Rock Springs Capital Management's CORT Position: Q2 2026 in Review

Rock Springs Capital Management increased its Corcept Therapeutics (CORT) stake by 43% in Q2 2026, buying an estimated $1.31M and bringing the position to 72,000 shares worth $6.26M. The position accounts for 0.31% of the portfolio, ranked #68.

Rock Springs Capital Management first reported a position in CORT in Q4 2025 and has held it in 3 quarters since. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Rock Springs Capital Management held 72,000 shares of Corcept Therapeutics worth $6.26M as of Q2 2026.
  • Rock Springs Capital Management bought 21,750 Corcept Therapeutics shares in Q2 2026, an estimated $1.31M.
  • Corcept Therapeutics made up 0.31% of Rock Springs Capital Management's portfolio in Q2 2026, its #68 holding.
  • Rock Springs Capital Management first reported a position in Corcept Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Rock Springs Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.